Cargando…

Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas

BACKGROUND: Chemotherapy resistance remains a major obstacle in the treatment of women with ovarian cancer. Establishing predictive markers of chemoresponse would help to individualize therapy and improve survival of ovarian cancer patients. Chemotherapy resistance in ovarian cancer has been studied...

Descripción completa

Detalles Bibliográficos
Autores principales:	Österberg, Lovisa, Levan, Kristina, Partheen, Karolina, Delle, Ulla, Olsson, Björn, Sundfeldt, Karin, Horvath, György
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770569/ https://www.ncbi.nlm.nih.gov/pubmed/19835627 http://dx.doi.org/10.1186/1471-2407-9-368

Ejemplares similares

External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas
por: Partheen, Karolina, et al.
Publicado: (2009)

Potential tumor biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ
por: Kristjansdottir, Björg, et al.
Publicado: (2013)

Early inflammatory response in epithelial ovarian tumor cyst fluids
por: Kristjánsdóttir, Björg, et al.
Publicado: (2014)

Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass
por: Partheen, Karolina, et al.
Publicado: (2011)

Ovarian cyst fluid is a rich proteome resource for detection of new tumor biomarkers
por: Kristjansdottir, Björg, et al.
Publicado: (2012)

Thrombocytosis as a prognostic marker in stage III and IV serous ovarian cancer
por: Digklia, Antonia, et al.
Publicado: (2014)

Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b
por: Levan, Kristina, et al.
Publicado: (2017)

Sulfation of O-glycans on Mucin-type Proteins From Serous Ovarian Epithelial Tumors
por: Thomsson, Kristina A., et al.
Publicado: (2021)

Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study
por: He, Xiaoli, et al.
Publicado: (2021)

Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer
por: McDonald, Megan E., et al.
Publicado: (2019)

The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors
por: Vitiazeva, Varvara, et al.
Publicado: (2015)

Comparison of stage III mucinous and serous ovarian cancer: a case-control study
por: Firat Cuylan, Zeliha, et al.
Publicado: (2018)

Outcomes of fertility-sparing surgery for stage II and III serous borderline ovarian tumors
por: Lu, Ziyang, et al.
Publicado: (2019)

Evaluation of Sialyl-Lactotetra as a Marker for Epithelial Ovarian Tumors
por: Barone, Angela, et al.
Publicado: (2020)

Paclitaxel plus Carboplatin Chemotherapy for Primary Peritoneal Carcinoma: A Study of 22 Cases and Comparison with Stage III–IV Ovarian Serous Carcinoma
por: Kawaguchi, R., et al.
Publicado: (2012)

Role of Neoadjuvant Chemotherapy in Ovarian Serous Cancer Followed by Debulking
por: Chauhan, Sonali, et al.
Publicado: (2022)

Chemotherapy is not necessary for early-stage serous and endometrioid ovarian cancer after undergoing comprehensive staging surgery
por: Li, Shuqing, et al.
Publicado: (2020)

Tissue Biomarkers in Prognostication of Serous Ovarian Cancer following Neoadjuvant Chemotherapy
por: Khandakar, Binny, et al.
Publicado: (2014)

Label-Free Quantification Mass Spectrometry Identifies Protein Markers of Chemotherapy Response in High-Grade Serous Ovarian Cancer
por: Arentz, Georgia, et al.
Publicado: (2023)

Discovery of Prognostic Markers for Early-Stage High-Grade Serous Ovarian Cancer by Maldi-Imaging
por: Kulbe, Hagen, et al.
Publicado: (2020)

Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance
por: Ricciardelli, Carmela, et al.
Publicado: (2017)

Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer
por: Vanguri, Rami, et al.
Publicado: (2022)

Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma
por: Kim, Yun-Sook, et al.
Publicado: (2010)

Gene expression profiling predicts a three-gene expression signature of endometrial adenocarcinoma in a rat model
por: Karlsson, Sandra, et al.
Publicado: (2009)

Classification of Tumor Samples from Expression Data Using Decision Trunks
por: Ulfenborg, Benjamin, et al.
Publicado: (2013)

Validation of suitable endogenous control genes for quantitative PCR analysis of microRNA gene expression in a rat model of endometrial cancer
por: Jurcevic, Sanja, et al.
Publicado: (2013)

MicroRNA expression in human endometrial adenocarcinoma
por: Jurcevic, Sanja, et al.
Publicado: (2014)

Prediction of chemo-response in serous ovarian cancer
por: Gonzalez Bosquet, Jesus, et al.
Publicado: (2016)

Does the primary route of spread have a prognostic significance in stage III non-serous epithelial ovarian cancer?
por: Sahin, Hanifi, et al.
Publicado: (2018)

Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status
por: Bock, Annika J., et al.
Publicado: (2011)

Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma
por: Marchocki, Zibi, et al.
Publicado: (2022)

Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients
por: Liutkauskiene, Sigita, et al.
Publicado: (2015)

Importance of Potential New Biomarkers in Patient with Serouse Ovarian Cancer
por: Cymbaluk-Płoska, Aneta, et al.
Publicado: (2021)

TGF-β isoforms induce EMT independent migration of ovarian cancer cells
por: Gao, Jingfang, et al.
Publicado: (2014)

USP19 and RPL23 as Candidate Prognostic Markers for Advanced-Stage High-Grade Serous Ovarian Carcinoma
por: Kang, Haeyoun, et al.
Publicado: (2021)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers
por: Miyamoto, M, et al.
Publicado: (2015)

High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers
por: Miyamoto, M, et al.
Publicado: (2017)

Evaluation of Ovarian Tumors with Multidetector Computed Tomography and Tumor Markers: Differentiation of Stage I Serous Borderline Tumors and Stage I Serous Malignant Tumors Presenting as Solid-Cystic Mass
por: Yu, Xin-Ping, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m7cpvk35krsb7pmv3r0287h6ve